BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-542@pharmaconomics
DTSTAMP:20260707T040437Z
DTSTART;VALUE=DATE:20260220
DTEND;VALUE=DATE:20260221
SUMMARY:BBIO Phase 3 — acoramidis
DESCRIPTION:Phase 3 trial results for acoramidis in transthyretin amyloid cardiomyopathy (ATTR-CM) are due Feb 20\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1743881/000174388126000008/bbio-20251231xex9911.htm\n\nTrack it: https://www.pharmaconomics.com/e/542
URL:https://www.pharmaconomics.com/e/542
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:BBIO catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR